Evidence map›Paper›PMID 34576930›Full record

ArticleMolecules (Basel, Switzerland)2021

Molecular Determinant of DIDS Analogs Targeting RAD51 Activity.

Denis Velic, Alexandre Demeyer, Thibaut Peterlini, Houda Benhelli-Mokrani, Monique Mathé-Allainmat, Jean-Yves Masson, Fabrice Fleury

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Denis VelicMechanism and Regulation of DNA Repair Team, UFIP, UMR 6286 CNRS, University of Nantes, F-44000 Nantes, France.
Alexandre DemeyerMechanism and Regulation of DNA Repair Team, UFIP, UMR 6286 CNRS, University of Nantes, F-44000 Nantes, France.
Thibaut PeterliniGenome Stability Laboratory, CHU de Québec Research Center, HDQ Pavilion, Oncology Division, 9 McMahon, Québec City, QC G1R 3S3, Canada.
Houda Benhelli-MokraniMechanism and Regulation of DNA Repair Team, UFIP, UMR 6286 CNRS, University of Nantes, F-44000 Nantes, France.ORCID 0000-0001-9501-0735
Monique Mathé-AllainmatCEISAM, UMR 6230 CNRS, University of Nantes, F-44000 Nantes, France.
Jean-Yves MassonGenome Stability Laboratory, CHU de Québec Research Center, HDQ Pavilion, Oncology Division, 9 McMahon, Québec City, QC G1R 3S3, Canada.
Fabrice FleuryMechanism and Regulation of DNA Repair Team, UFIP, UMR 6286 CNRS, University of Nantes, F-44000 Nantes, France.ORCID 0000-0002-6764-5060
Centre National de la Recherche Scientifique · FRUniversité Laval · CA

Funding

Conseil Régional des Pays de la Loire PIRAMID programSamuel de Champlain program 2011/130/SCAC
6 · The paper itself

Abstract

RAD51 is the central protein in DNA repair by homologous recombination (HR), involved in several steps of this process. It is shown that overexpression of the RAD51 protein is correlated with increased survival of cancer cells to cancer treatments. For the past decade, RAD51 overexpression-mediated resistance has justified the development of targeted inhibitors. One of the first molecules described to inhibit RAD51 was the 4,4'-diisothiocyanato-stilbene-2,2'-disulfonic acid (DIDS) molecule. This small molecule is effective in inhibiting different functions of RAD51, however its mode of action and the chemical functions involved in this inhibition have not been identified. In this work, we used several commercial molecules derived from DIDS to characterize the structural determinants involved in modulating the activity of RAD51. By combining biochemical and biophysical approaches, we have shown that DIDS and two analogs were able to inhibit the binding of RAD51 to ssDNA and prevent the formation of D-loop by RAD51. Both isothiocyanate substituents of DIDS appear to be essential in the inhibition of RAD51. These results open the way to the synthesis of new molecules derived from DIDS that should be greater modulators of RAD51 and more efficient for HR inhibition.

Indexed as

4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic AcidDNA, Single-StrandedDose-Response Relationship, DrugRad51 Recombinase4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic AcidDNA, Single-StrandedRAD51 protein, humanRad51 RecombinasecancerinhibitorRAD51recombinase activitystilbene derivatives

Identifiers

PMID34576930
PMCPMC8466854
OpenAlexW3197561900

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.